Emerging drugs for diabetic macular edema

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Diabetic macular edema (DME) is the most common cause of visual impairment due to diabetic retinopathy. The treatment of DME has recently undergone a paradigm shift. Traditionally, photocoagulation was standard treatment, but pharmacologic therapies are becoming increasingly used for this purpose. All currently available drug therapies for DME are either anti-VEGF agents or corticosteroids. Areas covered: The pathogenesis of DME involves angiogenesis, inflammation and oxidative stress. The scientific rationale to treat DME through the pharmacologic blockade of VEGF and other pro-angiogenic factors is discussed. The fluocinolone insert is approved for the treatment of DME in several European countries, but not in the US at this time. Some medications that are already approved for other retinal diseases, most prominently aflibercept and the dexamethasone delivery system, have recently obtained approval for DME in the US. Other compounds are being studied in earlier-phase clinical trials. Expert opinion: Pharmacologic treatment of DME will likely become increasingly used, especially for patients with edema involving the fovea. At this time, the two main classes of medication for treatment of DME are anti-VEGF agents and corticosteroids. As we continue to collect clinical trials data, the precise role of individual agents, and the continuing role for photocoagulation, will become more clear.

Original languageEnglish
Pages (from-to)397-405
Number of pages9
JournalExpert Opinion on Emerging Drugs
Volume19
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Macular Edema
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Light Coagulation
Adrenal Cortex Hormones
Therapeutics
Clinical Trials
Retinal Diseases
Angiogenesis Inducing Agents
Vision Disorders
Expert Testimony
Diabetic Retinopathy
Dexamethasone
Edema
Oxidative Stress
Inflammation
Drug Therapy

Keywords

  • Aflibercept
  • Bevacizumab
  • Dexamethasone
  • Diabetic macular edema
  • Fluocinolone acetonide
  • Randomized clinical trial
  • Ranibizumab
  • Triamcinolone acetonide
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for diabetic macular edema. / Schwartz, Stephen; Flynn, Harry W; Scott, Ingrid U.

In: Expert Opinion on Emerging Drugs, Vol. 19, No. 3, 01.01.2014, p. 397-405.

Research output: Contribution to journalArticle

@article{52fb28316e8d45a7af139e0022bd8d2f,
title = "Emerging drugs for diabetic macular edema",
abstract = "Introduction: Diabetic macular edema (DME) is the most common cause of visual impairment due to diabetic retinopathy. The treatment of DME has recently undergone a paradigm shift. Traditionally, photocoagulation was standard treatment, but pharmacologic therapies are becoming increasingly used for this purpose. All currently available drug therapies for DME are either anti-VEGF agents or corticosteroids. Areas covered: The pathogenesis of DME involves angiogenesis, inflammation and oxidative stress. The scientific rationale to treat DME through the pharmacologic blockade of VEGF and other pro-angiogenic factors is discussed. The fluocinolone insert is approved for the treatment of DME in several European countries, but not in the US at this time. Some medications that are already approved for other retinal diseases, most prominently aflibercept and the dexamethasone delivery system, have recently obtained approval for DME in the US. Other compounds are being studied in earlier-phase clinical trials. Expert opinion: Pharmacologic treatment of DME will likely become increasingly used, especially for patients with edema involving the fovea. At this time, the two main classes of medication for treatment of DME are anti-VEGF agents and corticosteroids. As we continue to collect clinical trials data, the precise role of individual agents, and the continuing role for photocoagulation, will become more clear.",
keywords = "Aflibercept, Bevacizumab, Dexamethasone, Diabetic macular edema, Fluocinolone acetonide, Randomized clinical trial, Ranibizumab, Triamcinolone acetonide, VEGF",
author = "Stephen Schwartz and Flynn, {Harry W} and Scott, {Ingrid U.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/14728214.2014.938048",
language = "English",
volume = "19",
pages = "397--405",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for diabetic macular edema

AU - Schwartz, Stephen

AU - Flynn, Harry W

AU - Scott, Ingrid U.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Diabetic macular edema (DME) is the most common cause of visual impairment due to diabetic retinopathy. The treatment of DME has recently undergone a paradigm shift. Traditionally, photocoagulation was standard treatment, but pharmacologic therapies are becoming increasingly used for this purpose. All currently available drug therapies for DME are either anti-VEGF agents or corticosteroids. Areas covered: The pathogenesis of DME involves angiogenesis, inflammation and oxidative stress. The scientific rationale to treat DME through the pharmacologic blockade of VEGF and other pro-angiogenic factors is discussed. The fluocinolone insert is approved for the treatment of DME in several European countries, but not in the US at this time. Some medications that are already approved for other retinal diseases, most prominently aflibercept and the dexamethasone delivery system, have recently obtained approval for DME in the US. Other compounds are being studied in earlier-phase clinical trials. Expert opinion: Pharmacologic treatment of DME will likely become increasingly used, especially for patients with edema involving the fovea. At this time, the two main classes of medication for treatment of DME are anti-VEGF agents and corticosteroids. As we continue to collect clinical trials data, the precise role of individual agents, and the continuing role for photocoagulation, will become more clear.

AB - Introduction: Diabetic macular edema (DME) is the most common cause of visual impairment due to diabetic retinopathy. The treatment of DME has recently undergone a paradigm shift. Traditionally, photocoagulation was standard treatment, but pharmacologic therapies are becoming increasingly used for this purpose. All currently available drug therapies for DME are either anti-VEGF agents or corticosteroids. Areas covered: The pathogenesis of DME involves angiogenesis, inflammation and oxidative stress. The scientific rationale to treat DME through the pharmacologic blockade of VEGF and other pro-angiogenic factors is discussed. The fluocinolone insert is approved for the treatment of DME in several European countries, but not in the US at this time. Some medications that are already approved for other retinal diseases, most prominently aflibercept and the dexamethasone delivery system, have recently obtained approval for DME in the US. Other compounds are being studied in earlier-phase clinical trials. Expert opinion: Pharmacologic treatment of DME will likely become increasingly used, especially for patients with edema involving the fovea. At this time, the two main classes of medication for treatment of DME are anti-VEGF agents and corticosteroids. As we continue to collect clinical trials data, the precise role of individual agents, and the continuing role for photocoagulation, will become more clear.

KW - Aflibercept

KW - Bevacizumab

KW - Dexamethasone

KW - Diabetic macular edema

KW - Fluocinolone acetonide

KW - Randomized clinical trial

KW - Ranibizumab

KW - Triamcinolone acetonide

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84906806277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906806277&partnerID=8YFLogxK

U2 - 10.1517/14728214.2014.938048

DO - 10.1517/14728214.2014.938048

M3 - Article

VL - 19

SP - 397

EP - 405

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -